The blood experts
Sanquin Pharma and Biotech Services (PBS) performs specialized services using an invaluable asset that we know inside and out: human blood. We assist clients in their early drug development and diagnostic challenges through the combination of an in-depth knowledge of blood, immunology, and disease mechanisms and access to state-of-the-art technology.
Blood has a story to tell, let us unravel it for you.
Sanquin Pharma and Biotech Services (PBS) performs specialized services using an invaluable asset that we know inside and out: human blood. We assist clients in their early drug development and diagnostic challenges through the combination of an in-depth knowledge of blood, immunology, and disease mechanisms and access to state-of-the-art technology.
Blood has a story to tell, let us unravel it for you.
Unraveling the story using the ABCs of blood
Sanquin Pharma and Biotech Services (PBS) performs specialized services using an invaluable asset that we know inside and out: human blood. We assist clients in their early drug development and diagnostic challenges through the combination of an in-depth knowledge of blood, immunology, and disease mechanisms and access to state-of-the-art technology.
Antibodies
Antibodies are important factors to consider in drug development. Even when they are not the drug itself or the focus of the drug’s method of action, antibodies play key roles in a drug’s efficacy and toxicity. Sanquin PBS can analyze both the functional and structural features of these antibodies, and dive deep into antibody effector functions.
Biomarkers
Biomarkers predict or explain desired or unwanted responses to your drug and track the mode of action of your compound. Catch any effects that could materialize at the early stages of your development process and use these to set up a patient stratification strategy.
Cells
Blood is a complex medium that facilitates numerous and cascading interactions. The cellular components of blood are the mediators of these interactions, representing both potential opportunities and obstacles to your therapeutic pipeline. Sanquin PBS has the know-how to treat cells for accurate analysis covering both the innate and adaptive immune systems and blood cells that can be difficult to study.
Together, these ABCs tell the complex stories
contained in blood
Sanquin PBS is your expert partner to tell many of these stories through our knowledge of blood and the immune system, from antibody modification to blood vessel morphology. We apply this specialization in areas including immune disorders, (immuno)hematology, oncology, immunomodulation therapies, and vaccines.
Some of our core capabilities include:
Assay & tool development
- Biomarker assays
- Cellular assays
- Pharmacokinetic (PK) assays
- Anti-drug antibodies (ADA) assays
- Diagnostic (companion, complementary, IVD), predictive, prognotic, safety, disease & drug mode of action, drug efficacy endpoints
- Design, selection, immunization & maturation
- Characterization
- Engineering
- Affinity & specificity
- Glycosylation
- Isotype, idiotype & allotype
In vitro/ ex vivo Studies
- On- and off-target binding
- Antibody-dependent cellular cytotoxicity (ADCC)
- Whole blood complement-dependent cytotoxicity (CDC)
- Complement-dependent cytotoxicity (CDC)
- Antibody-mediated cellular phagocytosis (ADCP)
- Biological (antibody) – target complexes
- Epitope detection & selection & validation
- Immunogenicity & pharmacokinetics
- Auto-antibodies
- Innate & Adaptive
- CD4+/CD8+ T-cell & B-cell response
- Immune cell populations (lymphocytes, monocytes, dendritic cells, granulocytes)
- Cell surface activation markers – functional state & responsiveness
- Cell-mediated cytotoxicity
- Functional assays
- Immune activation and inflammation response biomarkers (multiplex)
- Antibody responses, isotypes and levels
- Immunopharmacology
- B-cell isolation, receptor sequencing and cloning
- Complement activation
- Proprietary MHC I toolset
- HLA Typing
- Peptide-MHC Binding assays
- (HLA combinatorial coded) Tetramer Staining
- Functional assays
- MHC cell expression
- Antigen presentation
- Whole blood assays
- Complement components (complement factors & activation markers)
- Complement pathways (lectin, classical & alternative pathway)
- Hemolytic assays
- Complement activation, depletion & inhibition
- Functional assays
- Complement-mediated cytotoxicity
- Opsonization
- Drug potency (inhibition/activation)
- Off the shelf and custom biological drug assays
- Pharmacokinetic analysis
- Immunogenicity
- Anti-drug antibodies (ADA)
- Biosimilar characterization
- Whole blood (multiplex) cytokine release assays
- Whole blood complement activation
- Screening assays for key biochemical and biomarker endpoints
- Monocyte Activation Test (MAT)
- Antibody-dependent cellular toxicity (ADCC)
- Hemostasis & fibrinolysis
- Cell viability & cytotoxicity
- Safety pharmacology (cardiovascular, respiratory, CNS, renal, hepatic, reproductive)
- Absorption, Distribution, metabolism, elimination & toxicity (ADME-Tox)
- Binding assays
- Enzyme activity
- Dose escalation, dose response & time course
- Disease biomarkers
- Receptor saturation
- Cell activation, proliferation & depletion
- Whole blood complement activation
Our experts in the ABCs of blood
Kyra A. Gelderman, PhD
Assay Development & Validation
Immune response & Immune effector mechanisms
Complement system
Biotherapeutics Monitoring
Toxicity testing
Annelies Turksma, PhD
Assay Development & Validation
Antibodies & their effector functions
Immune response & Immune effector mechanisms
Major Histocompatibility Complex (MHC) & Human Leukocyte Antigen (HLA)
Biotherapeutics Monitoring
Toxicity testing
Pharmacokinetic/ Pharmacodynamic (PK/PD) studies
Marijke Molenaar-de Backer, PhD
Assay Development & Validation
Immune response & Immune effector mechanisms
Biotherapeutics Monitoring
Toxicity testing
Monocyte Activation Test
Annick de Vries, PhD
Assay Development & Validation
Biotherapeutics Monitoring
Pharmacokinetic/ Pharmacodynamic (PK/PD) studies
Immunogenicity
Karien Bloem, PhD
Assay Development & Validation
Antibody development & engineering
Biotherapeutics Monitoring
Pharmacokinetic/ Pharmacodynamic (PK/PD) studies
Immunogenicity
Floris Loeff, PhD
Assay Development & Validation
Immune response & Immune effector mechanisms
Biotherapeutics Monitoring
Pharmacokinetic/ Pharmacodynamic (PK/PD) studies
Immunogenicity